Neurology Central

Age/disease duration influence on activities of daily living and quality of life after levodopa-carbidopa intestinal gel in Parkinson’s disease

Does a patient’s age and disease duration in Parkinson’s affect the efficacy of their treatment with levodopa-carbidopa intestinal gel? Antonini et al. conducted a post hoc analysis of patient data from the GLORIA study to evaluate the impact of these factors on quality of life and activity of daily living outcomes. Read the abstract below to find out more on this new study, or read the full-text article in Neurodegenerative Disease Management here.

Aim: To determine if age and Parkinson’s disease duration at therapy initiation influence the efficacy of levodopa-carbidopa intestinal gel (LCIG) on quality of life and activities of daily living. Patients & methods: This post hoc analysis assessed subgroups of patients stratified by baseline age, disease duration, hours/day of ‘off’ time and levodopa equivalent dose. Patients’ data were collected from the GLORIA study, a 24-month observational registry evaluating long-term effectiveness of LCIG. Results & conclusion: LCIG therapy led to sustained improvements in quality of life irrespective of patient age and disease duration at baseline. Improvements in activities of daily living were observed across all subgroups, particularly in younger patients, patients with shorter disease duration and in patients with the highest baseline levodopa equivalent dose.

Click here to read the full article from Neurodegenerative Disease Management.


1 Comment

  1. Levocarbidopa es un farmaco utilizado en trastorno de Parkinson por mas de medio siglo, siendo que esta demostrado que los IMAO son muy superiores en cuanto a su efectividad y carentes de los efectos secundarios de dicho precursor de dopamina, (generacion de tolerancia, induccion de cuadros psicoticos,etc.). La pregunta es porque se sigue utilizando ?

Reply To jorge munoz esteves Cancel Reply